Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Feb;79(2):367–373. doi: 10.1172/JCI112821

Galactose ingestion increases vascular permeability and collagen solubility in normal male rats.

K Chang, M Tomlinson, J R Jeffrey, R G Tilton, W R Sherman, K E Ackermann, R A Berger, T J Cicero, C Kilo, J R Williamson
PMCID: PMC424075  PMID: 3100575

Abstract

In view of the similarity of cataracts and neuropathy in galactose-fed and diabetic rats, the present experiments were undertaken to determine whether consumption of galactose-enriched diets (10, 25, or 50% by weight) also increases collagen crosslinking and permeation of vessels by 125I-albumin analogous to that observed in diabetic rats. The observations in these experiments: demonstrate that consumption of galactose-enriched diets for 3 wk selectively increases 125I-albumin permeation of the same vascular beds affected in diabetic rats and by diabetic vascular disease in humans (i.e., the aorta and vessels in the eye, kidney, sciatic nerve, and new tissue formed in the diabetic milieu); demonstrate that the susceptibility of the vasculature to aldose reductase-linked injury (increased permeability) varies greatly in different tissues; indicate that collagen solubility (crosslinking) changes in galactose-fed rats differ sharply from those in diabetic rats; and provide new evidence that consumption of galactose-enriched diets induces a hypogonadal state in male rats.

Full text

PDF
367

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akagi Y., Kador P. F., Kuwabara T., Kinoshita J. H. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci. 1983 Nov;24(11):1516–1519. [PubMed] [Google Scholar]
  2. Berg R. A. Determination of 3- and 4-hydroxyproline. Methods Enzymol. 1982;82(Pt A):372–398. doi: 10.1016/0076-6879(82)82074-0. [DOI] [PubMed] [Google Scholar]
  3. Beyer-Mears A., Ku L., Cohen M. P. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. Diabetes. 1984 Jun;33(6):604–607. doi: 10.2337/diab.33.6.604. [DOI] [PubMed] [Google Scholar]
  4. Broekhuyse R. M. Changes in myo-inositol permeability in the lens due to cataractous conditions. Biochim Biophys Acta. 1968 Sep 17;163(2):269–272. doi: 10.1016/0005-2736(68)90107-7. [DOI] [PubMed] [Google Scholar]
  5. Chang K., Uitto J., Rowold E. A., Grant G. A., Kilo C., Williamson J. R. Increased collagen cross-linkages in experimental diabetes: reversal by beta-aminopropionitrile and D-penicillamine. Diabetes. 1980 Oct;29(10):778–781. doi: 10.2337/diacare.20.10.778. [DOI] [PubMed] [Google Scholar]
  6. Cicero T. J., Meyer E. R., Wiest W. G., Olney J. W., Bell R. D. Effects of chronic morphine administration on the reproductive system of the male rat. J Pharmacol Exp Ther. 1975 Mar;192(3):542–548. [PubMed] [Google Scholar]
  7. Clements R. S., Jr, Morrison A. D., Winegrad A. I. Polyol pathway in aorta: regulation by hormones. Science. 1969 Nov 21;166(3908):1007–1008. doi: 10.1126/science.166.3908.1007. [DOI] [PubMed] [Google Scholar]
  8. Cogan D. G., Kinoshita J. H., Kador P. F., Robison G., Datilis M. B., Cobo L. M., Kupfer C. NIH conference. Aldose reductase and complications of diabetes. Ann Intern Med. 1984 Jul;101(1):82–91. doi: 10.7326/0003-4819-101-1-82. [DOI] [PubMed] [Google Scholar]
  9. Cogan D. G., Kinoshita J. H., Kador P. F., Robison G., Datilis M. B., Cobo L. M., Kupfer C. NIH conference. Aldose reductase and complications of diabetes. Ann Intern Med. 1984 Jul;101(1):82–91. doi: 10.7326/0003-4819-101-1-82. [DOI] [PubMed] [Google Scholar]
  10. Crabbe M. J., Wolff S., Halder A. B., Ting H. H. Diabetic cataracts- is aldose reductase important? Metab Pediatr Ophthalmol. 1981;5(1):33–38. [PubMed] [Google Scholar]
  11. Das B., Srivastava S. K. Activation of aldose reductase from human tissues. Diabetes. 1985 Nov;34(11):1145–1151. doi: 10.2337/diab.34.11.1145. [DOI] [PubMed] [Google Scholar]
  12. Dvornik E., Simard-Duquesne N., Krami M., Sestanj K., Gabbay K. H., Kinoshita J. H., Varma S. D., Merola L. O. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science. 1973 Dec 14;182(4117):1146–1148. doi: 10.1126/science.182.4117.1146. [DOI] [PubMed] [Google Scholar]
  13. Dyck P. J., Sherman W. R., Hallcher L. M., Service F. J., O'Brien P. C., Grina L. A., Palumbo P. J., Swanson C. J. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol. 1980 Dec;8(6):590–596. doi: 10.1002/ana.410080608. [DOI] [PubMed] [Google Scholar]
  14. Engerman R. L., Kramer J. W. Dogs with induced or spontaneous diabetes as models for the study of human diabetes mellitus. Diabetes. 1982;31(Suppl 1 Pt 2):26–29. doi: 10.2337/diab.31.1.s26. [DOI] [PubMed] [Google Scholar]
  15. Flückiger R., Winterhalter K. H. In vitro synthesis of hemoglobin AIc. FEBS Lett. 1976 Dec 1;71(2):356–360. doi: 10.1016/0014-5793(76)80969-6. [DOI] [PubMed] [Google Scholar]
  16. Frank R. N., Keirn R. J., Kennedy A., Frank K. W. Galactose-induced retinal capillary basement membrane thickening: prevention by Sorbinil. Invest Ophthalmol Vis Sci. 1983 Nov;24(11):1519–1524. [PubMed] [Google Scholar]
  17. Frenkel G. P., Homonnai Z. T., Drasnin N., Sofer A., Kaplan R., Kraicer P. F. Fertility of the streptozotocin-diabetic male rat. Andrologia. 1978 Mar-Apr;10(2):127–136. doi: 10.1111/j.1439-0272.1978.tb01327.x. [DOI] [PubMed] [Google Scholar]
  18. Gabbay K. H. The sorbitol pathway and the complications of diabetes. N Engl J Med. 1973 Apr 19;288(16):831–836. doi: 10.1056/NEJM197304192881609. [DOI] [PubMed] [Google Scholar]
  19. Gonzalez A. M., Sochor M., McLean P. The effect of an aldose reductase inhibitor (Sorbinil) on the level of metabolites in lenses of diabetic rats. Diabetes. 1983 May;32(5):482–485. doi: 10.2337/diab.32.5.482. [DOI] [PubMed] [Google Scholar]
  20. González R. G., Barnett P., Aguayo J., Cheng H. M., Chylack L. T., Jr Direct measurement of polyol pathway activity in the ocular lens. Diabetes. 1984 Feb;33(2):196–199. doi: 10.2337/diab.33.2.196. [DOI] [PubMed] [Google Scholar]
  21. Greene D. A., Lattimer S., Ulbrecht J., Carroll P. Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care. 1985 May-Jun;8(3):290–299. doi: 10.2337/diacare.8.3.290. [DOI] [PubMed] [Google Scholar]
  22. HAYMAN S., KINOSHITA J. H. ISOLATION AND PROPERTIES OF LENS ALDOSE REDUCTASE. J Biol Chem. 1965 Feb;240:877–882. [PubMed] [Google Scholar]
  23. HUGGETT A. S., NIXON D. A. Use of glucose oxidase, peroxidase, and O-dianisidine in determination of blood and urinary glucose. Lancet. 1957 Aug 24;273(6991):368–370. doi: 10.1016/s0140-6736(57)92595-3. [DOI] [PubMed] [Google Scholar]
  24. Howland B. E., Zebrowski E. J. Some effects of experimentally-induced diabetes on pituitary-testicular relationships in rats. Horm Metab Res. 1976 Nov;8(6):465–469. doi: 10.1055/s-0028-1093597. [DOI] [PubMed] [Google Scholar]
  25. Jakobsen J., Malmgren L., Olsson Y. Permeability of the blood-nerve barrier in the streptozotocin-diabetic rat. Exp Neurol. 1978 Jun;60(2):277–285. doi: 10.1016/0014-4886(78)90083-3. [DOI] [PubMed] [Google Scholar]
  26. Judzewitsch R. G., Jaspan J. B., Polonsky K. S., Weinberg C. R., Halter J. B., Halar E., Pfeifer M. A., Vukadinovic C., Bernstein L., Schneider M. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med. 1983 Jan 20;308(3):119–125. doi: 10.1056/NEJM198301203080302. [DOI] [PubMed] [Google Scholar]
  27. Kennedy A., Frank R. N., Varma S. D. Aldose reductase activity in retinal and cerebral microvessels and cultured vascular cells. Invest Ophthalmol Vis Sci. 1983 Sep;24(9):1250–1258. [PubMed] [Google Scholar]
  28. Kern T. S., Engerman R. L. Hexitol production by canine retinal microvessels. Invest Ophthalmol Vis Sci. 1985 Mar;26(3):382–384. [PubMed] [Google Scholar]
  29. Kikkawa R., Hatanaka I., Yasuda H., Kobayashi N., Shigeta Y., Terashima H., Morimura T., Tsuboshima M. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia. 1983 Apr;24(4):290–292. doi: 10.1007/BF00282716. [DOI] [PubMed] [Google Scholar]
  30. Kilzer P., Chang K., Marvel J., Kilo C., Williamson J. R. Tissue differences in vascular permeability changes induced by histamine. Microvasc Res. 1985 Nov;30(3):270–285. doi: 10.1016/0026-2862(85)90059-7. [DOI] [PubMed] [Google Scholar]
  31. Kilzer P., Chang K., Marvel J., Rowold E., Jaudes P., Ullensvang S., Kilo C., Williamson J. R. Albumin permeation of new vessels is increased in diabetic rats. Diabetes. 1985 Apr;34(4):333–336. doi: 10.2337/diab.34.4.333. [DOI] [PubMed] [Google Scholar]
  32. Kinoshita J. H. Cataracts in galactosemia. The Jonas S. Friedenwald Memorial Lecture. Invest Ophthalmol. 1965 Oct;4(5):786–799. [PubMed] [Google Scholar]
  33. Kivirikko K. I., Laitinen O., Prockop D. J. Modifications of a specific assay for hydroxyproline in urine. Anal Biochem. 1967 May;19(2):249–255. doi: 10.1016/0003-2697(67)90160-1. [DOI] [PubMed] [Google Scholar]
  34. Kohner E. M., Dollery C. T., Paterson J. W., Oakley N. W. Arterial fluorescein studies in diabetic retinopathy. Diabetes. 1967 Jan;16(1):1–10. doi: 10.2337/diab.16.1.1. [DOI] [PubMed] [Google Scholar]
  35. Ludvigson M. A., Sorenson R. L. Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes. 1980 Jun;29(6):450–459. doi: 10.2337/diab.29.6.450. [DOI] [PubMed] [Google Scholar]
  36. MOORE S., STEIN W. H. A modified ninhydrin reagent for the photometric determination of amino acids and related compounds. J Biol Chem. 1954 Dec;211(2):907–913. [PubMed] [Google Scholar]
  37. Malmgren L. T., Jakobsen J., Olsson Y. Permeability of blood-nerve barrier in galactose-fed rats. Exp Neurol. 1979 Dec;66(3):758–770. doi: 10.1016/0014-4886(79)90219-x. [DOI] [PubMed] [Google Scholar]
  38. Miller E. J., Rhodes R. K. Preparation and characterization of the different types of collagen. Methods Enzymol. 1982;82(Pt A):33–64. doi: 10.1016/0076-6879(82)82059-4. [DOI] [PubMed] [Google Scholar]
  39. Norton E. W., Gutman F. Diabetic retinopathy studied by fluorescein angiography. Ophthalmologica. 1965;150(1):5–17. doi: 10.1159/000304822. [DOI] [PubMed] [Google Scholar]
  40. Ohi T., Poduslo J. F., Dyck P. J. Increased endoneurial albumin in diabetic polyneuropathy. Neurology. 1985 Dec;35(12):1790–1791. doi: 10.1212/wnl.35.12.1790. [DOI] [PubMed] [Google Scholar]
  41. Peterson M. J., Sarges R., Aldinger C. E., MacDonald D. P. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Metabolism. 1979 Apr;28(4 Suppl 1):456–461. doi: 10.1016/0026-0495(79)90056-8. [DOI] [PubMed] [Google Scholar]
  42. Robison W. G., Jr, Kador P. F., Akagi Y., Kinoshita J. H., Gonzalez R., Dvornik D. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes. 1986 Mar;35(3):295–299. doi: 10.2337/diab.35.3.295. [DOI] [PubMed] [Google Scholar]
  43. Robison W. G., Jr, Kador P. F., Kinoshita J. H. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science. 1983 Sep 16;221(4616):1177–1179. doi: 10.1126/science.6612330. [DOI] [PubMed] [Google Scholar]
  44. SMITH M. G. Polyol dehydrogenases. 4. Crystallization of the L-iditol dehydrogenase of sheep liver. Biochem J. 1962 Apr;83:135–144. doi: 10.1042/bj0830135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. STERLING R. E., DAY P. L. Blood sugar levels and cataract in alloxan-treated, galactose-fed and xylose-fed weanling rats. Proc Soc Exp Biol Med. 1951 Nov;78(2):431–433. doi: 10.3181/00379727-78-19094. [DOI] [PubMed] [Google Scholar]
  46. Saksena S. K., Lau I. F. Variations in serum androgens, estrogens, progestins, gonadotropins and prolactin levels in male rats from prepubertal to advanced age. Exp Aging Res. 1979 Jun;5(3):179–194. doi: 10.1080/03610737908257197. [DOI] [PubMed] [Google Scholar]
  47. Seneviratne K. N. Permeability of blood nerve barriers in the diabetic rat. J Neurol Neurosurg Psychiatry. 1972 Apr;35(2):156–162. doi: 10.1136/jnnp.35.2.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sharma A. K., Thomas P. K., Baker R. W. Peripheral nerve abnormalities related to galactose administration in rats. J Neurol Neurosurg Psychiatry. 1976 Aug;39(8):794–802. doi: 10.1136/jnnp.39.8.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Simard-Duquesne N., Greselin E., Gonzalez R., Dvornik D. Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat. Proc Soc Exp Biol Med. 1985 Apr;178(4):599–605. doi: 10.3181/00379727-178-42048. [DOI] [PubMed] [Google Scholar]
  50. Stewart M. A., Sherman W. R., Kurien M. M., Moonsammy G. I., Wisgerhof M. Polyol accumulations in nervous tissue of rats with experimental diabetes and galactosaemia. J Neurochem. 1967 Nov;14(11):1057–1066. doi: 10.1111/j.1471-4159.1967.tb09516.x. [DOI] [PubMed] [Google Scholar]
  51. Stribling D., Mirrlees D. J., Harrison H. E., Earl D. C. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism. 1985 Apr;34(4):336–344. doi: 10.1016/0026-0495(85)90223-9. [DOI] [PubMed] [Google Scholar]
  52. Tomlinson D. R., Moriarty R. J., Mayer J. H. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Diabetes. 1984 May;33(5):470–476. doi: 10.2337/diab.33.5.470. [DOI] [PubMed] [Google Scholar]
  53. Williamson J. R., Chang K., Rowold E., Marvel J., Tomlinson M., Sherman W. R., Ackermann K. E., Kilo C. Diabetes-induced increases in vascular permeability and changes in granulation tissue levels of sorbitol, myo-inositol, chiro-inositol, and scyllo-inositol are prevented by sorbinil. Metabolism. 1986 Apr;35(4 Suppl 1):41–45. doi: 10.1016/0026-0495(86)90186-1. [DOI] [PubMed] [Google Scholar]
  54. Williamson J. R., Chang K., Rowold E., Marvel J., Tomlinson M., Sherman W. R., Ackermann K. E., Kilo C. Sorbinil prevents diabetes-induced increases in vascular permeability but does not alter collagen cross-linking. Diabetes. 1985 Jul;34(7):703–705. doi: 10.2337/diab.34.7.703. [DOI] [PubMed] [Google Scholar]
  55. Williamson J. R., Rowold E., Chang K., Marvel J., Tomlinson M., Sherman W. R., Ackermann K. E., Berger R. A., Kilo C. Sex steroid dependency of diabetes-induced changes in polyol metabolism, vascular permeability, and collagen cross-linking. Diabetes. 1986 Jan;35(1):20–27. doi: 10.2337/diab.35.1.20. [DOI] [PubMed] [Google Scholar]
  56. Winegrad A. I., Simmons D. A., Martin D. B. Has one diabetic complication been explained? N Engl J Med. 1983 Jan 20;308(3):152–154. doi: 10.1056/NEJM198301203080309. [DOI] [PubMed] [Google Scholar]
  57. Yue D. K., Hanwell M. A., Satchell P. M., Turtle J. R. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes. 1982 Sep;31(9):789–794. doi: 10.2337/diab.31.9.789. [DOI] [PubMed] [Google Scholar]
  58. de VERDIER C., HJELM M. A galactose-oxidase method for the determination of galactose in blood plasma. Clin Chim Acta. 1962 Sep;7:742–744. doi: 10.1016/0009-8981(62)90165-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES